Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
Public ClinicalTrials.gov record NCT02814916. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections
Study identification
- NCT ID
- NCT02814916
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 199 participants
Conditions and interventions
Conditions
Interventions
- Cefadroxil Drug
- Clindamycin Drug
- Dalbavancin Drug
- Flucloxacillin Drug
- Oxacillin Drug
- Vancomycin Drug
Drug
Eligibility (public fields only)
- Age range
- 0 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2017
- Primary completion
- Dec 31, 2023
- Completion
- Dec 31, 2023
- Last update posted
- Sep 18, 2024
2017 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Alabama /ID# 237446 | Mobile | Alabama | 36604-3302 | — |
| Valleywise Health Medical Center /ID# 234343 | Phoenix | Arizona | 85008-4973 | — |
| Southbay Pharma Research /ID# 235700 | La Palma | California | 90623 | — |
| University of California, Los Angeles /ID# 237533 | Los Angeles | California | 90095 | — |
| Duplicate_Children's Hospital Colorado /ID# 237622 | Aurora | Colorado | 80045 | — |
| Global Research Holdings LLC /ID# 235747 | Panama City | Florida | 32405 | — |
| Tampa General Hospital /ID# 237061 | Tampa | Florida | 33606 | — |
| Children's Healthcare of Atlanta - Ferry Rd /ID# 237003 | Atlanta | Georgia | 30342-1605 | — |
| University of Maryland Medical Center /ID# 234353 | Baltimore | Maryland | 21201-1544 | — |
| Duplicate_Children's Mercy Hospital and Clinics /ID# 237800 | Kansas City | Missouri | 64108 | — |
| Robert Wood Johnson Univ Hosp /ID# 237862 | New Brunswick | New Jersey | 08901 | — |
| NYU School of Medicine /ID# 236783 | New York | New York | 10016 | — |
| SUNY Upstate Medical University /ID# 236831 | Syracuse | New York | 13210 | — |
| Duke University Medical Center /ID# 234315 | Durham | North Carolina | 27705-4410 | — |
| Cleveland Clinic Main Campus /ID# 237564 | Cleveland | Ohio | 44195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02814916, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2024 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02814916 live on ClinicalTrials.gov.